Magnetic seizure therapy (MST) was discovered to fare no improved than electroconvulsive therapy (ECT) for therapy-resistant depression, according to benefits from a complete intervention evaluation published in the Cochrane Database of Systematic Reviews.
MST is deemed an option to ECT, which is a “last resort” due to linked cognitive adverse effects such as amnesia and disorientation.
The authors searched electronic databases for published, unpublished, and ongoing research, as properly as research and relevant systematic evaluations and conference proceedings of the annual meeting of the American College of Neuropsychopharmacology, the annual scientific convention and meeting, and the annual meeting of the European College of Neuropsychopharmacology. The authors discovered 3 research that compared MST with ECT for therapy-resistant depression in adults.
The authors reported skewed information and an imbalance in baseline qualities in one particular study. In evaluating the remaining 2 research, the authors discovered no clear variations in depressive symptoms involving therapy groups (imply distinction, .71 95% CI, -2.23 to 3.65 2 research, 40 participants pretty-low-certainty proof).
Analysis of instant and delayed memory overall performance showed no clear distinction involving MST and ECT. Quality of life was also not substantially unique involving the research.
“Large, long, well-designed, and well-reported trials are needed to further examine the effects of MST,” the authors concluded.
Jiang J, Zhang C, Li C, et al. Magnetic seizure therapy for treatment-resistant depression. Cochrane Database Syst Rev. Published on the web June 16, 2021. doi:10.1002/14651858.CD013528.pub2.